Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PHOTOLEG

Financiado

Cerrado

Development of Photochromic Ligands for Selectively Expressed Glutamate Receptor...

Development of Photochromic Ligands for Selectively Expressed Glutamate Receptors As life expectancies across the world continue to increase, the number of people suffering from a degenerative neurological disorder such as Parkinson’s disease and Alzheimer’s disease also rapidly increases. This is a significant... ver más

30/04/2016

LMU MUENCHEN

162K€

Presupuesto del proyecto: 162K€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-04-30 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LMU MUENCHEN

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCIN-2015-163-C02-01 MODULADORES FOTOCONMUTABLES SINTETICOS PARA MANIPULAR REMOTA... 81K€ Cerrado

OPTOFRAX Optopharmacological brain mapping of autism mouse models 170K€ Cerrado

SAF2014-55700-P FARMACOLOGIA MULTIMODAL BASADA EN LA OLIGOMERIZACION DE RECE... 242K€ Cerrado

BIO2017-91475-EXP PEPTIDOS HELICOIDALES PARA CURAR LA ENFERMEDAD DE PARKINSON 30K€ Cerrado

BES-2016-076253 IMPLICACION DE LOS RECEPTORES ACOPLADOS A PROTEINAS G Y SUS... 93K€ Cerrado

PCIN-2015-163-C02-02 MODULADORES FOTOCONMUTABLES SINTETICOS PARA MANIPULAR REMOTA... 174K€ Cerrado

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 162K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto As life expectancies across the world continue to increase, the number of people suffering from a degenerative neurological disorder such as Parkinson’s disease and Alzheimer’s disease also rapidly increases. This is a significant problem (particularly in the developed world), with sufferers regularly experiencing a poor quality of life which often leaves them requiring costly round-the-clock care. Current pharmaceuticals have had some success in treating specific neurological disorders, but their effects are significantly limited as they generally only slow the progression of the disease. Consequently, there is a significant need for new and innovative methods to treat these debilitating neurological conditions. Researchers have established that some neurological disorders are caused by the break-down of neural networks in the brain. This has since been linked to the malfunction of glutamate receptors (GluRs) found in the cell membranes of neurons. In this Fellowship, we propose that new families of photochromic ligands (PCLs) that selectively and reversibly control GluRs using light, could be used to 'reactivate' unresponsive neural networks in the brain, allowing for the development of new and pioneering treatments for neurological disorders. To accomplish this we will develop new PCLs that are 'turned-on' by low energy 'red-shifted' light and then are rapidly 'turned-off' in the dark. This will significantly advance the current state of the art PCLs which are 'turned-on' in the dark, making them unsuitable for therapeutic applications. The new PCLs will target GluRs that are selectively expressed in particular cell types in the brain that are linked with the onset of degenerative neurological diseases. This will allow us to extensively study the role these GluRs play in the onset of neurological disorders, thus enabling us to develop new methods to treat these debilitating diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores